hotspot -WSS

hotspot

author：focus 2025-10-01 22:50:16 - browse：51

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Bird flu surveillance in wastewater gets boost from consortium

WSS

New weight loss drugs work. But how can they best be used?

As a primary care physician, here's how I hope to partner with AI

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Feng Zhang CRISPR delivery startup lays off quarter of staff

J&J to buy cancer drug developer Ambrx Biopharma

ASCO eve: Let’s set the table for this year's meeting

explore

hotspot

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

AdventHealth escalates lawsuit against insurance vendor Multiplan

Anesthesiologist group: stop taking Ozempic before surgery

Cue Health, Covid

Heart attack and stroke risk calculators need revising

Listen: More tumult at BIO & coercive care for sickle cell patients

Affirmative action in medical school literally saved lives

UCB departs biotech trade group BIO

Affirmative action in medical school literally saved lives

Burning questions for the 2024 JPM Healthcare Conference

entertainment

Burning questions for the 2024 JPM Healthcare Conference

Addressing health care workers' trauma can help fight burnout

UCB departs biotech trade group BIO

H5N1 bird flu outbreak: Second human case reported, in Michigan

Fentanyl is making it harder to start addiction treatment

The biotech scorecard for Q1: 17 stock

Wikipedia

leisure time

entertainment

focus